REGISTER FOR THE 2024 CONFERENCE
Shopping Cart

No products in the cart.

Cachexia

From Molecular Insights to Clinical Strategies: Delve into the complexities of cachexia, encompassing cancer cachexia, molecular mechanisms, and evolving therapeutic approaches. Discover the forefront of research aimed at understanding and combating this debilitating condition.

AllAgeingCachexiaCancer CachexiaClinical TrialsExerciseFrailtyFrom the literatureGuidelinesMuscleNutritionOther SCWD EventsSarcopenia

Harnessing the Systemic Biology of Functional Decline and Cachexia to Inform more Holistic Therapies for Incurable Cancers.

Options for treatment of incurable cancer remain scarce and are largely focused on limited therapeutic mechanisms. A new approach specific to advanced cancers is needed to identify new and effective treatments. Morbidity in advanced cancer is driven by functional decline...

๐Ÿ—“๏ธ 2024-01-14
Read MoreHarnessing the Systemic Biology of Functional Decline and Cachexia to Inform more Holistic Therapies for Incurable Cancers.

Assessment of lipolysis biomarkers in adipose tissue of patients with gastrointestinal cancer.

Adipose tissue metabolism may be impaired in patients with cancer. In particular, increased lipolysis was described in cancer-promoting adipose tissue atrophy. For this reason, we assessed the expression of the lipolysis-associated genes and proteins in subcutaneous adipose tissue (SAT) of...

๐Ÿ—“๏ธ 2024-01-02
Read MoreAssessment of lipolysis biomarkers in adipose tissue of patients with gastrointestinal cancer.

Prevalence and prognosis of cachexia according to the Asian Working Group for Cachexia criteria in sarcopenic dysphagia: A retrospective cohort study.

The aim is to examine the prevalence and prognosis of cachexia according to the Asian Working Group for Cachexia (AWGC) criteria in patients with sarcopenic dysphagia. A retrospective cohort study was conducted with 271 patients diagnosed with sarcopenic dysphagia out...

๐Ÿ—“๏ธ 2024-02-06
๐Ÿ“ฐ Publication: Nutrition
Read MorePrevalence and prognosis of cachexia according to the Asian Working Group for Cachexia criteria in sarcopenic dysphagia: A retrospective cohort study.

Increased Expression of Proinflammatory Genes in Peripheral Blood Cells Is Associated with Cardiac Cachexia in Patients with Heart Failure with Reduced Ejection Fraction.

: Cardiac cachexia (CC) in chronic heart failure with reduced ejection fraction (HFrEF) is characterized by catabolism and inflammation predicting poor prognosis. Levels of responsible transcription factors like signal transducer and activator of transcription (STAT)1, STAT3, suppressor of cytokine signaling...

๐Ÿ—“๏ธ 2024-01-27
Read MoreIncreased Expression of Proinflammatory Genes in Peripheral Blood Cells Is Associated with Cardiac Cachexia in Patients with Heart Failure with Reduced Ejection Fraction.

Factors associated with multimodal care practices for cancer cachexia among registered dietitians.

This study aimed to determine factors associated with multimodal care practices for cancer cachexia among registered dietitians (RDs) working in cancer care. A secondary analysis was performed using RDs' data. Data on knowledge, skills, and confidence in multimodal care were...

๐Ÿ—“๏ธ 2024-03-06
๐Ÿ“ฐ Publication: Supportive Care In Cancer
Read MoreFactors associated with multimodal care practices for cancer cachexia among registered dietitians.

Impacts of fluid retention on prognostic abilities of cachexia diagnostic criteria in cancer patients with refractory cachexia.

The international cancer cachexia criteria with a cutoff of 5% weight loss (WL) was proposed in Western patients. The Asian Working Group for Cachexia (AWGC) developed new criteria in Asian patients. The AWGC criteria are not cancer-specific and employ a...

๐Ÿ—“๏ธ 2024-02-29
Read MoreImpacts of fluid retention on prognostic abilities of cachexia diagnostic criteria in cancer patients with refractory cachexia.

Fluid retention and weight loss in refractory cancer cachexia.

It is unknown to what extent the fluid retention (FR) status disrupts the detection of weight loss rate (WLR) in adult patients with advanced cancer. This study aimed to determine the association of FR status with WLR. This study was...

๐Ÿ—“๏ธ 2024-02-23
๐Ÿ“ฐ Publication: Bmj Supportive & Palliative Care
Read MoreFluid retention and weight loss in refractory cancer cachexia.

Cachexia and Sarcopenia in Oligometastatic Non-Small Cell Lung Cancer: Making a Potential Curable Disease Incurable?

Among patients with advanced NSCLC, there is a group of patients with synchronous oligometastatic disease (sOMD), defined as a limited number of metastases detected at the time of diagnosis. As cachexia and sarcopenia are linked to poor survival, incorporating this...

๐Ÿ—“๏ธ 2024-01-04
Read MoreCachexia and Sarcopenia in Oligometastatic Non-Small Cell Lung Cancer: Making a Potential Curable Disease Incurable?
Cachexia: A systemic consequence of progressive, unresolved disease

Cachexia: A systemic consequence of progressive, unresolved disease

Cachexia, a systemic wasting condition, is considered a late consequence of diseases, including cancer, organ failure, or infections, and contributes to significant morbidity and mortality. The induction process and mechanistic progression of cachexia are incompletely understood. Refocusing academic efforts away...

๐Ÿ—“๏ธ 2023-04-27
๐Ÿ“ฐ Publication: Cell
Read MoreCachexia: A systemic consequence of progressive, unresolved disease

Body composition and lung cancer-associated cachexia in TRACERx.

Cancer-associated cachexia (CAC) is a major contributor to morbidity and mortality in individuals with non-small cell lung cancer. Key features of CAC include alterations in body composition and body weight. Here, we explore the association between body composition and body...

๐Ÿ—“๏ธ 2023-04-12
๐Ÿ“ฐ Publication: Nat Med
Read MoreBody composition and lung cancer-associated cachexia in TRACERx.

NAD repletion with niacin counteracts cancer cachexia.

Cachexia is a debilitating wasting syndrome and highly prevalent comorbidity in cancer patients. It manifests especially with energy and mitochondrial metabolism aberrations that promote tissue wasting. We recently identified nicotinamide adenine dinucleotide (NAD) loss to associate with muscle mitochondrial dysfunction...

๐Ÿ—“๏ธ 2023-04-03
๐Ÿ“ฐ Publication: Nat Commun
Read MoreNAD repletion with niacin counteracts cancer cachexia.

Assessing the Clinical Relevance of the C-Reactive Protein-Triglyceride-Glucose Index in Cancer Cachexia

This research uncovers the clinical significance of the C-reactive protein-triglyceride-glucose index (CTI) in predicting survival outcomes in cancer cachexia (CC). Demonstrating superior predictive accuracy over CRP or TyG indices alone, the study reveals CTI's correlation with increased mortality risks and its potential to refine patient management strategies in CC. Published in 'Cancer and Metabolism', January 2024, by Ruan GT, Deng L, Xie HL, et al., this work highlights CTI's pivotal role in enhancing prognosis and guiding treatment in CC.

๐Ÿ—“๏ธ January 2024
๐Ÿ“ฐ Publication: Cancer and Metabolism
Read MoreAssessing the Clinical Relevance of the C-Reactive Protein-Triglyceride-Glucose Index in Cancer Cachexia

Cancer Cachexia: Molecular Mechanisms and Therapeutic Strategies

This comprehensive review sheds light on cancer cachexia (CC), a significant condition marked by muscle wasting in cancer patients, emphasizing its molecular mechanisms and potential treatments. Highlighting the challenge CC presents, especially in older individuals, the article discusses the multifaceted approach needed to combat this syndrome.

๐Ÿ—“๏ธ January 2024
๐Ÿ“ฐ Publication: Clinical Nutrition
Read MoreCancer Cachexia: Molecular Mechanisms and Therapeutic Strategies

CACHEXIA DEFINITION

Cachexia has been defined as a loss of lean tissue mass, involving a weight loss greater than 5% of body weight in 12โ€‰months or less in the presence of chronic illness or as a body mass index (BMI) lower than 20โ€‰kg/m2. In addition, usually three of the following five criteria are required: decreased muscle strength, fatigue, anorexia, low fat-free mass index, increase of inflammation markers such as C-reactive protein or interleukin (IL)-6 as well as anaemia or low serum albumin.

Cachexia can occur in most major diseases including infections, cancer, heart disease, chronic kidney disease, chronic obstructive pulmonary disease, and stroke.

REFERENCES
Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008;27:793โ€“799

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489โ€“495.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!